Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
| 726.96 | |
| 699.63 | |
| - | |
| 730.96 | |
| 699.66 | |
| 315.8-972 | |
| 51 325 M | |
| 70 647 K | |
| 76 870 K | |
| -3.77 | |
| 0.541 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s designed to work differently from those currently on the market and with the p...
Zealand Pharma Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Com...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
